Table 4 Studies evaluating parity as a determinant of maternal or neonatal PFAS concentrations by PFAS, study design, and findings

Legacy PFAS

 PFOA (C/L)

–

–

10

[42, 61, 62, 65, 73, 76, 78, 81, 82, 88]

–

–

 PFOA (C-S)

–

–

5

[64, 66, 72, 74, 94]

8

[67, 77, 83, 86, 87, 89, 91, 92]

 PFOS (C/L)

–

–

10

[42, 61, 62, 65, 73, 76, 78, 81, 82, 88]

–

–

 PFOS (C-S)

1

[87]

4

[66, 72, 91, 94]

8

[64, 67, 74, 77, 83, 86, 89, 92]

 PFNA (C/L)

–

–

8

[62, 65, 73, 76, 78, 81, 82, 88]

1

[42]

 PFNA (C-S)

2

[87, 89]

2

[66, 94]

7

[64, 72, 74, 77, 83, 86, 91]

 PFHxS (C/L)

–

–

7

[61, 62, 73, 76, 78, 81, 82]

3

[42, 65, 88]

 PFHxS (C-S)

–

–

3

[66, 74, 94]

7

[77, 83, 86, 87, 89, 91, 94]

Other PFAS

 Et-PFOSA-AcOH (C/L)

1

[78]

1

[65]

–

–

 Me-PFOSA-AcOH (C/L)

1

[78]

–

–

1

[42]

 NMeFOSAA (C-S)

–

–

–

–

1

[74]

 PFDeA (C/L)

–

–

3

[65, 73, 82]

–

–

 PFDeA (C-S)

1

[87]

–

–

1

[74]

 PFDoA (C/L)

–

–

1

[73]

3

[73, 82, 88]

 PFDoA (C-S)

–

–

–

–

2

[87, 88]

 PFHpA (C/L)

–

–

–

–

1

[73]

 PFHpS (C/L)

–

–

1

[65]

–

–

 PFPeA (C-S)

–

–

–

–

2

[74, 77]

 PFTrDA (C/L)

–

–

–

–

1

[82]

 PFTrDA (C-S)

–

–

–

–

1

[87]

 PFUnDA (C/L)

–

–

3

[65, 73, 88]

1

[82]

 PFUnDA (C-S)

1

[87]

–

–

3

[64, 74, 89]

 6:2 Cl-PFESA (C/L)

–

–

1

[88]

–

–

 ΣPFAS (C-S)

1

[87]

–

–

–

–